Skip to content
Research/Peptides/Hexarelin

Hexarelin

Examorelin. Potent GHRP/ghrelin mimetic; also activates CD36 receptor for cardioprotection. GH release, muscle growth, cardioprotective. Research peptide.

Intelligence Profile

Science

Mechanism of Action

Hexarelin is a synthetic growth hormone-releasing peptide (GHRP) that acts through multiple molecular pathways, with its primary mechanism involving modulation of the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis.

Primary Growth Hormone Pathway
The available evidence indicates hexarelin functions as a growth hormone secretagogue, working through the GH-IGF1 axis to promote various physiological effects. A 2026 review in Frontiers in Endocrinology discusses hexarelin among performance-enhancing peptides that modulate this critical hormonal pathway, though specific molecular details of receptor binding are not detailed in the provided evidence.

Cytoprotective Mechanisms
Research demonstrates hexarelin exerts protective effects through several distinct molecular pathways:

  • MDM2/p53 Pathway: A 2023 study in the European Journal of Medical Research showed hexarelin alleviates apoptosis in ischemic acute kidney injury by modulating the MDM2/p53 pathway, suggesting it can influence cell death mechanisms at the molecular level.

  • Neuroprotective Actions: Evidence from 2026 research in the Indian Journal of Pharmacology indicates hexarelin promotes survival of retinal ganglion cells after optic nerve transection, pointing to neuroprotective mechanisms, though the specific molecular targets are not fully elucidated in the available evidence.

  • Neuroblastoma Cell Protection: A 2023 study in the International Journal of Molecular Sciences demonstrated protective effects in human neuroblastoma cells expressing the SOD1-G93A mutated protein, suggesting potential therapeutic mechanisms in neurodegenerative conditions.

Cardiovascular Effects
Research using synchrotron radiation imaging techniques published in Frontiers in Physiology (2021) has investigated hexarelin's actions in cardiac tissue of small animal models, though the specific molecular mechanisms underlying these cardiovascular effects are not detailed in the provided evidence.

Limitations in Current Evidence
The available evidence provides insight into hexarelin's physiological effects and some pathway involvement (particularly MDM2/p53), but lacks comprehensive detail about its specific receptor binding mechanisms, downstream signaling cascades, and complete molecular pharmacology. Further research would be needed to fully characterize its mechanism of action at the molecular level.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for any medical decisions.